Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/12036
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMelo, Andreia Cristina de-
dc.contributor.authorThuler, Luiz Claudio Santos-
dc.contributor.authorSilva, Jesse Lopes da-
dc.contributor.authorAlbuquerque, Lucas Zanetti de-
dc.contributor.authorPecego, Ana Carla-
dc.contributor.authorRodrigues, Luciana de Oliveira Ramadas-
dc.contributor.authorConceição, Magda de Souza da-
dc.contributor.authorGarrido, Marianne Monteiro-
dc.contributor.authorMendes, Gélcio Luiz Quintella-
dc.contributor.authorPereira, Ana Cristina Pinho Mendes-
dc.contributor.authorSoares, Marcelo Alves-
dc.contributor.authorViola, Joao Paulo de Biaso-
dc.date.accessioned2022-12-23T16:41:41Z-
dc.date.available2022-12-23T16:41:41Z-
dc.date.issued2020-10-26-
dc.identifier.issn1932-6203-
dc.identifier.urihttps://ninho.inca.gov.br/jspui/handle/123456789/12036-
dc.description.abstractObjective: This study aimed to describe the demographic and clinical characteristics of cancer inpatients with COVID-19 exploring clinical outcomes. Methods: A retrospective search in the electronic medical records of cancer inpatients admitted to the Brazilian National Cancer Institute from April 30, 2020 to May 26, 2020 granted identification of 181 patients with COVID-19 confirmed by RT-PCR. Results: The mean age was 55.3 years (SD ± 21.1). Comorbidities were present in 110 (60.8%) cases. The most prevalent solid tumors were breast (40 [22.1%]), gastrointestinal (24 [13.3%]), and gynecological (22 [12.2%]). Among hematological malignancies, lymphoma (20 [11%]) and leukemia (10 [5.5%]) predominated. Metastatic disease accounted for 90 (49.7%) cases. In total, 63 (34.8%) had recently received cytotoxic chemotherapy. The most common complications were respiratory failure (70 [38.7%]), septic shock (40 [22.1%]) and acute kidney injury (33 [18.2%]). A total of 60 (33.1%) patients died due to COVID-19 complications. For solid tumors, the COVID-19-specific mortality rate was 37.7% (52 out of 138 patients) and for hematological malignancies, 23.5% (8 out of 34). According to the univariate analysis COVID-19-specific mortality was significantly associated with age over 75 years (P = .002), metastatic cancer (p <0.001), two or more sites of metastases (P < .001), the presence of lung (P < .001) or bone metastases (P = .001), non-curative treatment or best supportive care intent (P < .001), higher C-reactive protein levels (P = .002), admission due to COVID-19 (P = .009), and antibiotics use (P = .02). After multivariate analysis, cases with admission due to symptoms of COVID-19 (P = .027) and with two or more metastatic sites (P < .001) showed a higher risk of COVID-19-specific death. Conclusion: This is the first Brazilian cohort of cancer patients with COVID-19. The rates of complications and COVID-19-specific death were significantly high.pt_BR
dc.subjectPacientes Internadospt_BR
dc.subjectInpatientspt_BR
dc.subjectCOVID-19pt_BR
dc.subjectNational Cancer Institute (U.S.)pt_BR
dc.subjectBrasilpt_BR
dc.subjectBrazilpt_BR
dc.subjectNeoplasias Gastrointestinaispt_BR
dc.subjectGastrointestinal Neoplasmspt_BR
dc.subjectExame Ginecológicopt_BR
dc.subjectGynecological Examinationpt_BR
dc.titleCancer inpatients with COVID-19: A report from the Brazilian National Cancer Institutept_BR
dc.TypeArticlept_BR
Appears in Collections:Artigos de Periódicos da Pesquisa Experimental e Translacional



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.